{"pageContent": "Background: Prostate cancer (PCa) is a leading cause of cancer death of men worldwide. In hormone-sensitive prostate cancer (HSPC), androgen deprivation therapy (ADT) is widely used, but an eventual failure on ADT heralds the passage to the castration-resistant prostate cancer (CRPC) stage. Because predicting time to failure on ADT would allow improved planning of personal treatment strategy, we aimed to develop a predictive personalization algorithm for ADT efficacy in HSPC patients.", "metaData": {"source": "Ultrasonically guided interstitial brachytherapy for prostate cancer: care of the patient in ambulatory surgery\nhttps://pubmed.ncbi.nlm.nih.gov/9801541/"}}